LifeTech Scientific Corporation
先 健 科 技 公 司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1302)

PROFIT WARNING

This announcement is made by the board (the "**Board**") of directors of LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board hereby informs the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the Group's unaudited consolidated management accounts for the six months ended 30 June 2026 and the preliminary assessment of information currently available to the Board, excluding certain non-recurring items stated below, the Group is expected to record a net profit attributable to owners of the Company of approximately RMB110.0 million to RMB120.0 million for the six months ended 30 June 2026, as compared with a net profit attributable to owners of the Company of approximately RMB238.5 million for the corresponding period of 2025. Such decrease was mainly attributable to (i) a decrease in revenue; and (ii) a significant decrease in net exchange gains.

The non-recurring items include share-based payment expenses, other gains or losses on financial assets at fair value through profit or loss, and expected transaction expenses in connection with the major transaction involving the acquisition of equity interest in Starway Medical Technology, Inc. (北京華醫聖傑科技有限公司) and the issue of convertible bonds, which the Board has resolved not to proceed with.

Taking into account the impact of such non-recurring items, the Group is expected to record a net loss attributable to owners of the Company of approximately RMB30.0 million to RMB40.0 million for the six months ended 30 June 2026, as compared with a net profit attributable to owners of the Company of approximately RMB55.1 million for the corresponding period of 2025.

The fluctuations in exchange differences and expected transaction expenses are of a short-term or one-off nature and do not affect the Group's long-term operations and financial position. The Board considers the Group's operational and financial position to be robust and remains optimistic about the Group's prospects as a whole.

The Board hereby reminds the Shareholders and potential investors of the Company that the information contained in this announcement is only based on a preliminary assessment made by the Board of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 and the information currently available to the management, which have not yet been audited or reviewed by the Company's independent auditors or the audit committee of the Company, and may be subject to further adjustments and modifications. Shareholders and potential investors are advised to refer to the Group's interim results for the six months ended 30 June 2026, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 12 August 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.